Brief: Seelos Therapeutics Receives European Orphan Drug Designation For Sls-005 (Trehalose) In Amyotrophic Lateral Sclerosis (Als)
27/05/2021 12:11
May 27 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS RECEIVES EUROPEAN ORPHAN DRUG
DESIGNATION
FOR SLS-005 (TREHALOSE) IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Source text for Eikon: ID:nPn2L6kGga
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio